Heidelberg Pharma reports early myeloma responses and selects a development dose
Heidelberg Pharma ($HPHA) presented Phase 1 results for pamlectabart tismanitin, its experimental antibody-drug conjugate for relapsed or refractory multiple myeloma. Among 31 evaluable patients in dose cohorts five through nine, 13 responded, giving an overall response rate of 42%. The wider dose-escalation analysis included 53 heavily pretreated patients, who had received a median of five prior treatment lines. The company selected 175 micrograms per kilogram for further development and said P
0